Cambridge researchers have discovered that an existing therapy which boosts protective immune cells in people who recently ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in ...

Drugs that limit the activity of cells called neutrophils could make heart attacks less severe without compromising the ...

Winter often arrives quietly, but its impact on health can be profound. As temperatures drop, cases of seasonal illnesses ...

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...

Cold weather and air pollution can worsen bronchial asthma. Here’s why winter triggers flare-ups and how patients can reduce ...

In asthma, airway inflammation leads to bronchoconstriction (narrowing of airways), excess mucus production and swelling of ...

(Alliance News) - GSK PLC on Tuesday said depemokimab, sold under the brand name Exdensur, has been approved by Japan's Ministry of Health, Labour and Welfare for severe asthma and chronic ...

GSK on Tuesday said Japan’s Ministry of Health, Labour and Welfare approved Exdensur, also known as depemokimab, for patients ...

Misunderstanding COPD and asthma can be risky. Recognising the difference in the condition, treatment options, and the need for early intervention is important.

A recent study revealed that popular GLP-1 weight-loss drugs may significantly minimise severe asthma attacks among teenagers ...

Patients with hereditary angioedema using deucrictibant as an on-demand treatment for attacks achieved onset of symptom ...